SCHEDULE: Dellora Funds Disclose Significant Stake in Tenax Therapeutics
Beneficial Ownership Disclosure
Dellora Investments Master Fund LP, Dellora Investments LP, and Kevin Pyun have disclosed beneficial ownership stakes of up to 6.4% in Tenax Therapeutics, Inc.
Summary
- Dellora Investments Master Fund LP beneficially owns 355,257 shares of Tenax Therapeutics, Inc. common stock, representing 5.7% of the class.
- Dellora Investments LP beneficially owns 401,071 shares of Tenax Therapeutics, Inc. common stock, representing 6.4% of the class.
- Kevin Pyun beneficially owns 401,071 shares of Tenax Therapeutics, Inc. common stock, representing 6.4% of the class.
- All reporting persons hold shared voting and shared dispositive power over their respective reported shares.
- The ownership percentages are based on 6,243,575 shares of common stock outstanding as of November 11, 2025, as reported by the Issuer in a Form 10-Q filed on November 12, 2025.
- Dellora Investments LP and Kevin Pyun expressly disclaim beneficial ownership over the reported securities, stating the filing is not an admission of such ownership.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a moderately positive signal, as significant institutional ownership can imply a degree of confidence in the company's prospects, even if the investment is passive.
Positives
- Significant institutional investment by Dellora Investments Master Fund LP, Dellora Investments LP, and Kevin Pyun, indicating a notable interest in Tenax Therapeutics, Inc.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine disclosures by institutional investors who acquire more than 5% of a company's stock, indicating a passive investment intent rather than an attempt to influence control. This filing signals Dellora Investments' significant, albeit passive, stake in Tenax Therapeutics, which can be viewed by the market as a vote of confidence or a strategic position.
Stakeholder Impact
- Shareholders: Increased institutional ownership may be perceived positively, potentially enhancing stock liquidity and investor confidence.
Key Dates
| Date | Description |
|---|---|
| 2025-11-11 | Date of shares outstanding calculation as per Issuer's Form 10-Q. |
| 2025-11-12 | Date Issuer filed Form 10-Q with the Securities and Exchange Commission. |
| 2025-12-31 | Date of event which required the filing of this statement. |
| 2026-02-17 | Date of filing and signature by reporting persons. |
Keywords
Tenax Therapeutics, Dellora Investments, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, TNXP
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.